Work overview

Section 05 of 08

Conclusion

Adjunctive palivizumab with ribavirin for respiratory syncytial virus infection during the early peri-transplant period in adult allogenic hematopoietic stem cell transplant recipients: Case series

Latefah Aleshaiwi, Afrah Alotaibi, Mohsen Alzahrani, Mohammad Bosaeed, Hajar AlQahtani, and Abdulellah Almohaya · 2026

Contents

Section 05 of 08

  1. 01Introduction
  2. 02Methods
  3. 03Cases (Summarized in Table 1)
  4. 04Discussion
  5. 05Conclusion
  6. 06CRediT authorship contribution statement
  7. 07Ethics declaration
  8. 08Declaration of Competing Interest
Text size
Work overview

Section 5 of 8

Conclusion

Latefah Aleshaiwi, Afrah Alotaibi, Mohsen Alzahrani, Mohammad Bosaeed, Hajar AlQahtani, and Abdulellah Almohaya · about 1 minutes

Original source ↗

In conclusion, the use of palivizumab could serve as an adjunct therapy in heavily immunosuppressed patients, particularly in the early post-stem cell transplantation. We did not note a significant signal of safety. Further prospective studies are needed to better define optimal management strategies, explore the role of intravenous rather than intramuscular palivizumab, and the role of adjunctive therapies in HSCT recipients with RSV infection.